Skip navigation.
Home

A Beginner's Guide to Growth Stocks

Come on, admit it: Like most of us, you gravitate toward the market's highfliers. You know, the stocks with sex appeal -- and price multiples that make those of the broader market look like the proverbial chicken feed. FedEx (NYSE: FDX), Gilead Sciences (Nasdaq: GILD), Comcast (Nasdaq: CMCSA), and Abbott Laboratories (NYSE: ABT), for example, all sport price-to-earnings (P/E) ratios that surpass the broader market's. Apollo Group (Nasdaq: APOL), American Tower (NYSE: AMT), and Genzyme (Nasdaq: GENZ) look even pricier by comparison.
Why are investors willing to pay such premiums? Well, earnings-growth estimates are typically a major factor, but don't discount the aforementioned sex appeal. Not for nothing do these stocks garner miles of column inches in the financial press.

How to proceed
If you find yourself besotted with racy growth stocks, your smartest move is to take a cold shower. Remember that the higher they fly, the farther they have to fall when Mr. Market takes a tumble. Just ask folks who invested in the growth-heavy Nasdaq 100 Trust (QQQQ) exchange-traded fund back in early 2000 -- right before the bottom fell out of the market. More than seven years later, those investors are still waiting to see a positive return on their investment.

The good news is that it doesn't have to be that way -- especially not these days. Large-cap stocks of the growth persuasion have been out of favor on a relative basis ever since the market experienced its pre-millennium meltdown. The upshot? Now appears to be an excellent time for investors to go growth shopping. After years of market-lagging performance, that seems to be where the market's bargains lie -- provided you know how to find them.

Three rules of thumb on that front are:

  1. Follow the cash flow. Among the big boys, favor growth-oriented companies with a proven ability to generate cash and plow sufficient sums back into expanding their businesses. That's a winning combination -- particularly if they hope to meet those outsized earnings estimates.
  2. Compare like with like. Seemingly above-average multiples can be misleading. A P/E of 25 looks high relative to the broader market's P/E (roughly 12), but not so much relative to, say, that of the average biotech company (roughly 57).
  3. Don't go whole hog. Be sure to own growth stocks in the context of a well-diversified portfolio that includes more mild-mannered fare. That's a smart way to work toward financial freedom -- and to get your beauty rest at night.
Copyright © 2008 Universal Press Syndicate.
( filed under: | )

Post new comment

Please solve the math problem above and type in the result. e.g. for 1+1, type 2
The content of this field is kept private and will not be shown publicly.

Recent comments